Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access Lenvatinib for First-Line Unresectable Hepatocellular Carcinoma
jRCT2080223705Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Eisai Co., Ltd. Started Nov 2017; status: completed.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080223705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223705.